Jean-Marc Vanacker

Dr. Jean-Marc Vanacker


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 1999 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
JVJean-Marc Vanacker
Jean-Marc Vanacker
KPKatarina Pettersson
Katarina Pettersson
JGJan‐Åke Gustafsson
Jan‐Åke Gustafsson
VLVincent Laudet
Vincent Laudet
The physiological activities of estrogens are thought to be mediated by specific nuclear receptors, ERα and ERβ. However, certain tissues, such as the bone, that are highly responsive to estrogens only express a low level of these receptors. Starting from this apparent contradiction, we have evaluated the potentials of two related receptors ERRα and ERRβ to intervene in estrogen signaling. ERα, ERRα and ERRβ bind to and activate transcription through both the classical estrogen response element (ERE) and the SF‐1 response element (SFRE). In contrast, ERβ DNA‐binding and transcriptional activity is restricted to the ERE. Accordingly, the osteopontin gene promoter is stimulated through SFRE sequences, by ERRα as well as by ERα, but not by ERβ. Analysis of the cross‐talk within the ER/ERR subgroup of nuclear receptors thus revealed common targets but also functional differences between the two ERs.

27 March 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JCJulie Carnesecchi
Julie Carnesecchi
CFChristelle Forcet
Christelle Forcet
LZLing Zhang
Ling Zhang
VTViolaine Tribollet
Violaine Tribollet
BBBruno Barenton
Bruno Barenton
JVJean-Marc Vanacker
Jean-Marc Vanacker
Significance: Dynamic demethylation of histone residues plays a crucial role in the regulation of gene expression. Lysine Specific Demethylase 1 (LSD1) can remove both transcriptionally permissive and repressive histone marks. How these activities are controlled is not clearly understood. Here, we show that the estrogen-related receptor α (ERRα) induces LSD1 to erase repressive marks in vitro. Through such a mechanism, LSD1 and ERRα commonly activate a set of transcriptional targets that include genes involved in the cellular capacity to invade the extracellular matrix. This process is a hallmark of cancer progression, to which high expression of both LSD1 and ERRα are strongly correlated.

1 August 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SBStéphanie Bianco
Stéphanie Bianco
OLOlivia Lanvin
Olivia Lanvin
VTViolaine Tribollet
Violaine Tribollet
CMClaire Macari
Claire Macari
SNSophie North
Sophie North
JVJean-Marc Vanacker
Jean-Marc Vanacker
High expression of the estrogen receptor-related receptor (ERR)-alpha in human tumors is correlated to a poor prognosis, suggesting an involvement of the receptor in cell proliferation. In this study, we show that a synthetic compound (XCT790) that modulates the activity of ERRalpha reduces the proliferation of various cell lines and blocks the G(1)/S transition of the cell cycle in an ERRalpha-dependent manner. XCT790 induces, in a p53-independent manner, the expression of the cell cycle inhibitor p21(waf/cip)(1) at the protein, mRNA, and promoter level, leading to an accumulation of hypophosphorylated Rb. Finally, XCT790 reduces cell tumorigenicity in Nude mice.

1 September 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
OLOlivia Lanvin
Olivia Lanvin
SBStéphanie Bianco
Stéphanie Bianco
NKNathalie Kersual
Nathalie Kersual
DCDany Chalbos
Dany Chalbos
JVJean-Marc Vanacker
Jean-Marc Vanacker
ICI182,780 (Fulvestrant) is a pure anti-estrogen used in adjuvant therapies of breast cancer. This compound not only inhibits the transcriptional activities of the estrogen receptor-α (ERα) but also induces its proteasome-dependent degradation. The latter activity is believed to be required for the antiproliferative effects of ICI182,780. Estrogen receptor-related receptor-α (ERRα) is an orphan member of the nuclear receptor superfamily that is expressed in a wide range of tissues including breast tumors, in which its high expression correlates with poor prognosis. Although not regulated by any natural ligand, ERRα can be deactivated by the synthetic molecule XCT790. Here we demonstrate that this compound also induces a proteasome degradation of ERRα. We also show that although it does not act directly on the steady-state level of ERα, XCT790 potentiates the ICI182,780-induced ERα degradation. We suggest that treatment with XCT790 could thus enhance the efficacy of ICI182,780 in ERα-dependent pathologies such as breast cancer.

6 October 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJuliette Sailland
Juliette Sailland
VTViolaine Tribollet
Violaine Tribollet
CFChristelle Forcet
Christelle Forcet
CBCyrielle Billon
Cyrielle Billon
BBBruno Barenton
Bruno Barenton
JVJean-Marc Vanacker
Jean-Marc Vanacker
Several physiopathological processes require orientated cellular migration. This phenomenon highly depends on members of the RHO family of GTPases. Both excessive and deficient RHO activity impair directional migration. A tight control is thus exerted on these proteins through the regulation of their activation and of their stability. Here we show that the estrogen-related receptor α (ERRα) directly activates the expression of TNFAIP1, the product of which [BTB/POZ domain-containing adapter for Cullin3-mediated RhoA degradation 2 (BACURD2)] regulates RHOA protein turnover. Inactivation of the receptor leads to enhanced RHOA stability and activation. This results in cell disorientation, increased actin network, and inability to form a lamellipodium at the migration edge. As a consequence, directional migration, but not cell motility per se, is impaired in the absence of the receptor, under pathological as well as physiological conditions. Altogether, our results show that the control exerted by ERRα on RHOA stability is required for directional migration. Significance Several developmental and physiological processes require that cells display a controlled ability to migrate in an orientated manner. This capacity is also reacquired by certain cancer cells during their progression toward aggressiveness that allows them to establish distant metastases. The Rho GTPases are instrumental in the control of orientated migration. Here, we demonstrate that the estrogen-related receptor α (ERRα), whose high expression correlates with tumor aggressiveness and poor prognosis, decreases the stability and activity of the RHOA protein and induces orientated cell migration. Together with other published data, our results show that inactivation of ERRα may reduce tumor aggressiveness.

20 November 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Catherine TeyssierCatherine Teyssier
Catherine Teyssier
MGMarlène Gallet
Marlène Gallet
BRBénédicte Rabier
Bénédicte Rabier
LMLaurent-Emmanuel Monfoulet
Laurent-Emmanuel Monfoulet
JDJulien Dine
Julien Dine
JVJean-Marc Vanacker
Jean-Marc Vanacker
ERRα is an orphan member of the nuclear hormone receptor superfamily, which acts as a transcription factor and is involved in various metabolic processes. ERRα is also highly expressed in ossification zones during mouse development as well as in human bones and cell lines. Previous data have shown that this receptor up-modulates the expression of osteopontin, which acts as an inhibitor of bone mineralization and whose absence results in resistance to ovariectomy-induced bone loss. Altogether this suggests that ERRα may negatively regulate bone mass and could impact on bone fragility that occurs in the absence of estrogens. In this report, we have determined the in vivo effect of ERRα on bone, using knock-out mice. Relative to wild type animals, female ERRαKO bones do not age and are resistant to bone loss induced by estrogen-withdrawal. Strikingly male ERRαKO mice are indistinguishable from their wild type counterparts, both at the unchallenged or gonadectomized state. Using primary cell cultures originating from ERRαKO bone marrow, we also show that ERRα acts as an inhibitor of osteoblast differentiation. Down-regulating ERRα could thus be beneficial against osteoporosis.